About half of people with gout don't have treatments that work. Meet the new gout drugs racing through trials to reach them.

Delve into what Merck has planned for the future of its pipeline as Keytruda's patent is getting closer to expiry.

The only TIL therapy approved so far is Amtagvi for melanoma. Here are six companies with promising TIL therapies in the ...

Roche's AXELIOS 1 enters next generation DNA sequencing. Can it or rivals unseat Illumina's long-standing market dominance?

With 10 cases in 2025, Guinea worm could be the second disease ever eradicated. Here is what makes disease eradication ...

There was a time when the numbers told an unoptimistic story about Roche. Its three oncology blockbusters, Herceptin, Avastin, and Rituxan, had built it into the world’s largest cancer drug maker, ...

So far, the visible strategy around bronchiectasis has been managing the problems it creates — mucus retention, repeated infections, airway inflammation, and exacerbations. Airway clearance, ...

In the heat of the COVID-19 crisis, a wave of vaccine companies stepped into the spotlight with unprecedented speed and visibility. Riding a surge of public and private funding, they raced to develop ...

Research in the field of inflammatory diseases has become one of the hottest areas of drug development, spurred on by an interest in novel therapies that have the potential to be more precise and more ...

Unlike traditional drugs that bind directly to a protein’s active site, allosteric modulators act at separate regulatory sites, allowing them to fine-tune biological activity and act more like a ...

Today, Akribion Therapeutics, a German biotech company announced its €8 million ($8.2 million) seed round. Akribion Therapeutics is working on G-dase E, a programmable nuclease designed to selectively ...